Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;1(3):251-9.
doi: 10.2147/copd.2006.1.3.251.

Use of Respimat Soft Mist inhaler in COPD patients

Paula Anderson  1
Affiliations
Review

Use of Respimat Soft Mist inhaler in COPD patients

Paula Anderson. Int J Chron Obstruct Pulmon Dis. 2006.

Abstract

Events of the past decade have stimulated development of new drug formulations and delivery devices that have improved the efficiency, ease of use, and environmental impact of inhaled drug therapy. Respimat Soft Mist Inhaler is a novel, multidose, propellant-free, hand-held, liquid inhaler that represents a new category of inhaler devices. The aerosol cloud generated by Respimat contains a higher fraction of fine particles than most pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs), and the aerosol spray exits the inhaler more slowly and for a longer duration than with pMDIs. This translates into higher lung drug deposition and lower oropharyngeal deposition, making it possible to give lower nominal doses of delivered drugs without lowering efficacy. In clinical trials in patients with COPD, bronchodilator drugs delivered from Respimat were equally effective at half of the dose delivered from a pMDI. In one study of inhaler preference, Respimat was preferred over the pMDI by patients with COPD and other obstructive lung diseases. Respimat is a valuable addition to the range of inhaler devices available to the patient with COPD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Respimat® Soft Mist Inhaler™. Reprinted from Dalby R, Spallek M, Voshaar T. 2004. A review of the development of Respimat® Soft Mist Inhaler™. Int J Pharm, 283:1–9. Copyright © 2004, with permission from Elsevier.
Figure 2
Figure 2
Schematic of Respimat® Soft Mist Inhaler™ showing the details of the uniblock. Reprinted from Dalby R, Spallek M, Voshaar T. 2004. A review of the development of Respimat® Soft Mist Inhaler™. Int J Pharm, 283:1–9. Copyright © 2004, with permission from Elsevier.
Figure 3
Figure 3
(a) Mean aerosol spray velocities at 10 cm from nozzle for Respimat® and various CFC- and HFA-pMDIs. (b) Mean spray duration for the devices. Reprinted from Hochrainer D, Hölz H, Kreher C, et al. 2005. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist Inhaler™ and pressurized metered dose inhalers. J Aerosol Med, 18:273–82. Copyright © 2005, with permission from Mary Ann Liebert, Inc. Abbreviations: CFC, chlorofluorocarbon; HFA, hydrofluoroalkane; pMDI, pressurized metered dose inhaler; SMI, Soft Mist™ inhaler.
Figure 4
Figure 4
Typical scintigraphic images for Respimat®, Turbuhaler® DPI at slow and fast inhaled flow rates, and CFC-pMDI. Reprinted from Pitcairn G, Reader S, Pavia D, et al. 2005. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared with deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med, 18:264–72. Copyright © 2005, with permission from Mary Ann Liebert, Inc. Abbreviations: CFC, chlorofluorocarbon; DPI, dry powder inhaler; pMDI, pressurized metered dose inhaler; SMI, Soft Mist™ inhaler.
Figure 5
Figure 5
Change in FEV1 from pre-dose value in first 60 minutes after dosing on day 85 for IB/FEN delivered by Respimat® (two doses) and by pMDI compared with placebo devices in COPD patients. Reprinted from Kilfeather SA, Ponitz HH, Beck E, et al. 2004. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ Inhaler in patients with COPD. Respir Med, 98:387–97. Copyright © 2004, with permission from Elsevier. Abbreviations: MDI, metered dose inhaler; SMI, Soft Mist™ inhaler.
See this image and copyright information in PMC

References

    1. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat® Soft Mist Inhaler™. Int J Pharm. 2004;283:1–9. - PubMed
    1. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127:335–71. - PubMed
    1. Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Resp Care. 2000;45:623–35. - PubMed
    1. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50:1360–74. - PubMed
    1. Goldberg J, Freund E, Beckers B, et al. Improved delivery of fenoterol plus ipratropium bromide using Respimat® compared with a conventional metered dose inhaler. Eur Respir J. 2001;17:225–32. - PubMed

MeSH terms

Substances